CTLA4-Ig is currently approved for the treatment of rheumatoid arthritis, but in SLE its benefits have been more difficult to establish, even though its immunosuppressive effects were first clearly established in lupus mouse models [15]. Here, CTLA4 is linked to systemic lupus erythematosus.